On October 31, 2019 Novavax, Inc. (Nasdaq: NVAX), a late stage biotechnology company developing next-generation vaccines for serious infectious diseases, reported it will report its third quarter 2019 financial and operating results following the close of U.S. financial markets on Thursday, November 7, 2019 (Press release, Novavax, OCT 31, 2019, http://ir.novavax.com/news-releases/news-release-details/novavax-host-conference-call-discuss-third-quarter-financial-2 [SID1234550183]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Conference call details are as follows:

Date: November 7, 2019
Time: 4:30 p.m. U.S. Eastern Time (ET)
Dial-in number: (877) 212-6076 (Domestic) or (707) 287-9331 (International)
Passcode: 5956098
Webcast: www.novavax.com, "Investors"/ "Events"

Conference call and webcast replay:

Dates: Starting at 7:30 p.m. ET, November 7, 2019 until
7:30 p.m. ET November 14, 2019
Dial-in number: (855) 859-2056 (Domestic) or (404) 537-3406 (International)
Passcode: 5956098
Webcast: www.novavax.com, "Investors"/ "Events", until February 7, 2020